Essential Site Maintenance: Authorea-powered sites will be updated circa 15:00-17:00 Eastern on Tuesday 5 November.
There should be no interruption to normal services, but please contact us at [email protected] in case you face any issues.

loading page

COPD and Herpes Zoster: Risk and Immunization
  • +4
  • Sneha Shrestha,
  • Abhigan Shrestha,
  • Abhyuday Yadav,
  • Suyesh Shrestha,
  • Selene Pokharel,
  • sajina shrestha,
  • Lok Shrestha
Sneha Shrestha
Kathmandu University School of Medical Sciences
Author Profile
Abhigan Shrestha
Dinajpur Medical College
Author Profile
Abhyuday Yadav
Kathmandu University School of Medical Sciences

Corresponding Author:[email protected]

Author Profile
Suyesh Shrestha
Kathmandu University Hospital
Author Profile
Selene Pokharel
Kathmandu University School of Medical Sciences
Author Profile
sajina shrestha
KIST Medical College
Author Profile
Lok Shrestha
University of New South Wales
Author Profile

Abstract

Varicella Zoster is a neurotropic virus which leads to acute varicella or it may lay dormant in the spinal root ganglion. Reactivation of varicella zoster causes Herpes Zoster (HZ) and occurs commonly in immunosuppressed conditions like COPD. Severity of Herpes Zoster is also higher among those with comorbidities like COPD. Even among COPD patients, the severity of HZ is said to be higher among those using oral corticosteroids than those using inhaled steroids due to greater immunosuppressive effect. It has also been found that incidence rate of COPD exacerbations, transient ischemic attack and stroke are higher among COPD patients with HZ compared to those without HZ. Herpes zoster vaccinations prevent reactivation of latent HZ and reduce the associated complications. Live attenuated and recombinant vaccines are available for vaccination among which recombinant vaccine is found to be more effective. The cost burden due to HZ among COPD patients was also higher compared to those without HZ. Childhood varicella vaccination is cost effective, however cost effectiveness of adolescent vaccination is unclear.
06 May 2023Submitted to Immunity, Inflammation and Disease
09 May 2023Submission Checks Completed
09 May 2023Assigned to Editor
13 May 2023Review(s) Completed, Editorial Evaluation Pending
18 May 2023Reviewer(s) Assigned
25 Jul 2023Editorial Decision: Revise Major
27 Sep 20231st Revision Received
04 Oct 2023Submission Checks Completed
04 Oct 2023Assigned to Editor
04 Oct 2023Review(s) Completed, Editorial Evaluation Pending
04 Oct 2023Reviewer(s) Assigned